FY2025 · period end Dec '25 · from the 10-K filed Feb 19, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.68B | $5.27B | $5.12B | $4.92B |
| Gross Profit | $3.43B | $3.16B | $2.93B | $2.94B | $2.94B |
| Operating Income | $1.10B | $1.04B | $0.93B | $1.06B | $1.14B |
| Net Income | $0.66B | $0.60B | $0.55B | $0.70B | $0.74B |
| EPS (Diluted) | $5.32 | $4.84 | $4.40 | $5.65 | $6.02 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $11.86B | $11.76B | $12.28B | $11.55B | $11.04B |
| Total Liabilities | $7.13B | $6.84B | $7.59B | $7.57B | $7.44B |
| Stockholders' Equity | $4.62B | $4.81B | $4.55B | $3.97B | $3.60B |
| Cash & Equivalents | $0.18B | $0.17B | $0.22B | $0.29B | $0.22B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.62B | $1.32B | $1.12B | $0.76B | $1.33B |
| Capital Expenditures | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 56.4% | 55.7% | 55.7% | 57.5% | 59.8% |
| Operating Margin | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% |
| Net Margin | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% |
| Return on Equity | 14.0% | 12.9% | 12.8% | 18.4% | 21.9% |
| Return on Assets | 5.6% | 5.0% | 4.6% | 6.2% | 7.2% |
| Debt / Equity | 0.88× | 0.90× | 1.04× | 1.21× | 1.24× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001193125-26-323760 | Jul 22, 2026 | Jul 29, 2026 | Jul 29, 2026 20:15 UTC | EDGAR |
| 8-K | 0000033185-26-000024 | Jul 21, 2026 | Jul 21, 2026 | Jul 21, 2026 10:32 UTC | EDGAR |
| 10-Q | 0000033185-26-000028 | Jun 30, 2026 | Jul 21, 2026 | Jul 21, 2026 20:39 UTC | EDGAR |
| 8-K | 0001193125-26-272759 | Jun 16, 2026 | Jun 16, 2026 | Jun 16, 2026 20:46 UTC | EDGAR |
| 8-K | 0001193125-26-220328 | May 7, 2026 | May 13, 2026 | May 13, 2026 01:52 UTC | EDGAR |
| 8-K | 0001193125-26-177620 | Apr 23, 2026 | Apr 24, 2026 | Apr 24, 2026 21:05 UTC | EDGAR |
| 8-K | 0000033185-26-000016 | Apr 21, 2026 | Apr 21, 2026 | Apr 21, 2026 10:32 UTC | EDGAR |
| 10-Q | 0000033185-26-000018 | Mar 31, 2026 | Apr 21, 2026 | Apr 21, 2026 20:30 UTC | EDGAR |
Direct links to SEC EDGAR. EFX has additional filings available on the SEC site.
6 numbers EQUIFAX INC later changed — same XBRL tag, both filings linked.
Net Income (Loss) Attributable to Parent·3 months to Dec 2019
Major restatementwas$9.2M
Revised up in a 10-K. Any P/E built on the original was 41.8% too high.
Net Cash Provided by (Used in) Operating Activities·Q1 2016
Major restatementwas$90.3M
Revised up in a 10-Q. Any P/OCF built on the original was 16.5% too high.
Net Cash Provided by (Used in) Operating Activities·Q1 2014
Major restatementwas$65M
Revised up in a 10-Q. Any P/OCF built on the original was 9.5% too high.
Net Cash Provided by (Used in) Operating Activities·Q2 2016
Notable restatementwas$279.5M
Revised up in a 10-Q. Any P/OCF built on the original was 6.4% too high.
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest·Q2 2020
Notable restatementwas$122.7M
Revised up in a 10-Q.
Net Income (Loss) Attributable to Parent·Q2 2020
Notable restatementwas$95.9M
Revised up in a 10-Q. Any P/E built on the original was 4.3% too high.
EFX is not the only one.
See every restatement we've found across the market — or get an alert the next time EFX revises a number.
Restatements are detected by comparing every vintage of a fact across all of EQUIFAX INC's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows EFX's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling EQUIFAX INC — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on EFX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on EFX and publish the result to your public profile.
Ask about EQUIFAX INC
Continue in Workspace — cited answers on EFX, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs